Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
- PMID: 35510099
- PMCID: PMC9042678
- DOI: 10.1016/j.prnil.2021.02.002
Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
Abstract
The expansion of the indication to use androgen deprivation therapy (ADT) to treat patients with advanced or metastatic prostate cancer has dramatically increased over the recent decades, resulting in the progress of patients' survival. However, chronic health implications can become more apparent as the number of long-term cancer survivors is expected to be increased along with the adverse effect of ADT. In particular, interest in investigating ADT, especially luteinizing hormone-releasing hormone (LHRH) agonist association with cognitive dysfunction has been growing. Previous studies in animals and humans suggest that the level of androgen decreases with age and that cognitive decline occurs with decreases in androgen. Correspondingly, some of the extensive studies using common neurocognitive tests have shown that LHRH agonists may affect specific domains of cognitive function (e.g., visuospatial abilities and executive function). However, the results from these studies have not consistently demonstrated the association because of its intrinsic limitations. Large-scale studies based on electronic databases have also failed to show consistent results to make decisive conclusions because of its heterogeneity, complexity of covariates, and possible risk of biases. Thus, this review article summarizes key findings and discusses the results of several studies investigating the ADT association with cognitive dysfunction and risk of dementia from various perspectives.
Keywords: AD, Alzheimer's disease; ADT, androgen deprivation therapy; Adverse effects; Androgen deprivation; Cognitive dysfunction; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; Dementia; HR, hazard ratio; LHRH, luteinizing hormone-releasing hormone; NHIS, National Health Insurance Service; PCa, Prostate cancer; Prostate cancer; SHBG, sex hormone-binding globulin.
© 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V.
Conflict of interest statement
Nothing to declare.
Figures
Similar articles
-
Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.Cancer Epidemiol. 2020 Feb;64:101657. doi: 10.1016/j.canep.2019.101657. Epub 2020 Jan 7. Cancer Epidemiol. 2020. PMID: 31918180
-
Intermittent androgen deprivation therapy in advanced prostate cancer.Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Curr Treat Options Oncol. 2014. PMID: 24395278 Review.
-
Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer.Curr Oncol Rep. 2020 Feb 11;22(3):24. doi: 10.1007/s11912-020-0884-1. Curr Oncol Rep. 2020. PMID: 32048059 Review.
-
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.
-
How Does Androgen Deprivation Therapy Affect Mental Health including Cognitive Dysfunction in Patients with Prostate Cancer?World J Mens Health. 2021 Oct;39(4):598-605. doi: 10.5534/wjmh.200092. Epub 2020 Jul 21. World J Mens Health. 2021. PMID: 32777867 Free PMC article. Review.
Cited by
-
Androgen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration?Am J Cancer Res. 2024 Jul 15;14(7):3652-3664. doi: 10.62347/WOLA8904. eCollection 2024. Am J Cancer Res. 2024. PMID: 39113873 Free PMC article.
-
Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients.Sci Rep. 2022 Jun 10;12(1):9567. doi: 10.1038/s41598-022-13361-4. Sci Rep. 2022. PMID: 35688928 Free PMC article.
-
Cognitive Impairment in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review.Cancers (Basel). 2025 Jul 29;17(15):2501. doi: 10.3390/cancers17152501. Cancers (Basel). 2025. PMID: 40805198 Free PMC article. Review.
-
The Effect of Testosterone Replacement on Sexual Function in the Elderly: A Systematic Review and Meta-Analysis.World J Mens Health. 2023 Oct;41(4):861-873. doi: 10.5534/wjmh.220171. Epub 2023 Jan 4. World J Mens Health. 2023. PMID: 36649923 Free PMC article.
-
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas). 2023 Dec 30;60(1):77. doi: 10.3390/medicina60010077. Medicina (Kaunas). 2023. PMID: 38256338 Free PMC article. Review.
References
-
- Jones C.U., Hunt D., McGowan D.G., Amin M.B., Chetner M.P., Bruner D.W., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–118. - PubMed
-
- Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous